Global Von Willebrand Disease (VWD) Treatment Market Report 2023: Increasing Public Awareness Related to VWD Drives Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031" report has been added to ResearchAndMarkets.com's offering.

The global Von Willebrand Disease (VWD) Treatment Market is expected to grow at 5.5% by 2031. According to World Federation of Hemophilia (WFH), von Willebrand disease (VWD) is the most common type of bleeding disorder.

Companies Mentioned

• Octapharma AG
• Crifols
• S.A.
• Shire plc
• Bayer AG
• CSL Behring
• Pfizer Inc.
• Akorn Inc.
• Ferring B.V.

People with VWD have a problem with a protein in their blood called von Willebrand factor (VWF) that helps control bleeding. When a blood vessel is injured and bleeding occurs, VWF helps cells in the blood, called platelets, mesh together and form a clot to stop the bleeding.

According to market experts, around 1% of the world's population suffers from VWD, but due to presence of very mild symptoms only a few number of patients are aware about the condition. Research has shown that as many as 9 out of 10 people with VWD have not been diagnosed.

On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD. The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.

Recently, the FDA has approved Bendeka (bendamustine) product of Teva and Eagle Pharmaceuticals, a novel drug formulation that can be administered via a shorter, lower-volume infusion - for chronic lymphocytic leukaemia and B-cell non-Hodgkin's lymphoma.It was observed that Teva received US commercialisation rights to Bendeka under a deal with Eagle signed in February, and plans to launch the therapy during the first quarter of 2016.

The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe. North America was observed as the largest market for von Willebrand disease treatment followed by Europe. Asia Pacific was anticipated to grow at a fastest CAGR during the forecast period 2016 to 2022.

The key factors assisting the growth of Asia Pacific von Willebrand disease treatment market are the rising awareness associated with the rare diseases, developing healthcare infrastructure, high disposable income and government support for novel treatment against rare genetic diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

Market Segmentation

Disease Type

• Type 1 von Willebrand Disease
• Type 2 von Willebrand Disease
• Type 3 von Willebrand Disease
• Acquired von Willebrand Disease

Drug

• Desmopressin
• Clot-stabilizing Medications
• Replacement Therapies
• Contraceptives
• Others

Route of Administration

• Oral
• Injection
• Others

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Von Willebrand Disease (VWD) Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2031.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Von Willebrand Disease (VWD) Treatment market?
• Which is the largest regional market for Von Willebrand Disease (VWD) Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Von Willebrand Disease (VWD) Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Von Willebrand Disease (VWD) Treatment market worldwide?

For more information about this report visit https://www.researchandmarkets.com/r/iq7l6w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.